Table 12.
Country | Gentamicin | Chloramphenicol | Ampicillin | Cefotaxime | Ceftazidime | Meropenem | Tigecycline | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Austria | 178 | 1.7 | 178 | 7.3 | 178 | 32.0 | 178 | 2.2 | 178 | 2.2 | 178 | 0 | 178 | 0 |
Belgium | 262 | 0.0 | 261 | 14.2 | 261 | 75.1 | 262 | 2.7 | 261 | 1.1 | 261 | 0 | – | – |
Cyprus | 39 | 5.1 | – | – | 40 | 37.5 | 7 | NA | 40 | 0 | 38 | 0 | – | – |
Denmark | 57 | 0 | 57 | 17.5 | 57 | 42.1 | 57 | 0 | 57 | 0 | 57 | 0 | 57 | 0 |
Estonia | 72 | 0 | 72 | 2.8 | 72 | 81.9 | 71 | 0 | 72 | 0 | 72 | 0 | – | – |
Finland | 57 | 0 | 57 | 7.0 | 57 | 10.5 | 57 | 0 | – | – | 57 | 0 | – | – |
France | 117 | 0 | 117 | 27.4 | 117 | 47.0 | 117 | 0.9 | 117 | 0.9 | 116 | 0 | 117 | 0.9 |
Germanya | 575 | 1.2 | 575 | 9.6 | 575 | 80.2 | 575 | 1.2 | 575 | 0.9 | 575 | 0 | – | – |
Greece | 17 | 0 | 17 | 0 | 17 | 35.3 | 17 | 5.9 | 17 | 5.9 | 17 | 0 | – | – |
Hungarya | 153 | 4.6 | 154 | 23.4 | 154 | 46.1 | 154 | 1.3 | 153 | 11.8 | 154 | 0 | – | – |
Ireland | 37 | 0 | 37 | 8.1 | 37 | 24.3 | 37 | 0 | 37 | 0 | 37 | 0 | 37 | 0 |
Italy | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | 1 | NA | – | – |
Latviaa | – | – | – | – | 6 | NA | 7 | NA | – | – | – | – | – | – |
Lithuaniaa | 52 | 0 | 71 | 8.5 | 139 | 81.3 | 96 | 0 | 71 | 0 | 43 | 0 | – | – |
Luxembourg | 21 | 0 | 21 | 19.0 | 21 | 38.1 | 21 | 0 | 21 | 0 | 21 | 0 | – | – |
Maltaa | – | – | – | – | 27 | 88.9 | 27 | 0 | 27 | 0 | 27 | 0 | – | – |
Netherlands | 196 | 1.0 | 196 | 26.0 | 196 | 46.4 | 196 | 0.5 | 196 | 0 | 196 | 0 | 196 | 0 |
Portugal | 55 | 0 | 55 | 20.0 | 55 | 72.7 | 55 | 0 | 55 | 0 | 55 | 0 | 55 | 0 |
Romania | 57 | 3.5 | 57 | 5.3 | 57 | 82.5 | 57 | 3.5 | 57 | 3.5 | 57 | 0 | – | – |
Slovakiaa | – | – | – | – | 38 | 65.8 | 10 | 20.0 | – | – | – | – | – | – |
Slovenia | 44 | 0 | 44 | 4.5 | 44 | 38.6 | 44 | 0 | 44 | 0 | 44 | 0a | – | – |
Spain | 58 | 0 | 58 | 48.3 | 58 | 65.5 | 58 | 3.4 | 58 | 0 | 58 | 0 | – | – |
United Kingdoma | – | – | 358 | 25.1 | 595 | 55.8 | 208 | 2.4 | 110 | 5.5 | 125 | 0 | – | – |
Total (MSs 23) | 2,048 | 1.1 | 2,386 | 16.2 | 2,802 | 60.6 | 2,312 | 1.5 | 2,147 | 1.9 | 2,189 | 0 | 640 | 0.2 |
Icelanda | – | – | 8 | NA | 8 | NA | – | – | – | – | – | – | – | – |
Norway | 34 | 5.9 | 13 | 46.2 | 34 | 23.5 | 34 | 0 | 34 | 0 | 34 | 0 | – | – |
Country | Nalidixic acid | Ciprofloxacinb | Azithromycin | Colistin | Sulfamethoxazolec | Trimethoprim | Co‐trimoxazole | Tetracycline | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | N | % Res | |
Austria | 178 | 4.5 | 126 | 6.3 | – | – | – | – | 178 | 33.1 | 178 | 4.5 | – | – | 178 | 34.3 |
Belgium | 262 | 2.3 | 262 | 6.5 | 261 | 0 | – | – | 262 | 51.9 | 94 | 31.9 | – | – | 262 | 55.0 |
Cyprus | – | – | – | – | – | – | 29 | 0 | – | – | – | – | – | – | 7 | 42.9 |
Denmark | 57 | 0 | 57 | 0 | 57 | 0.0 | 57 | 0 | 57 | 38.6 | 57 | 5.3 | – | – | 57 | 40.4 |
Estonia | 64 | 84.4 | 72 | 75.0 | – | – | 72 | 0 | 72 | 81.9 | 72 | 79.2 | – | – | 72 | 81.9 |
Finland | 57 | 15.8 | 57 | 17.5 | – | – | – | – | – | – | 57 | 3.5 | – | – | 57 | 8.8 |
France | 117 | 7.7 | 117 | 8.5 | 117 | 0.9 | 117 | 0.9 | 117 | 59.8 | 117 | 15.4 | – | – | 117 | 49.6 |
Germanya | 574 | 4.2 | 574 | 0.2 | – | – | – | – | – | – | – | – | 575 | 13.2 | 573 | 60.7 |
Greece | 17 | 5.9 | 17 | 0 | – | – | – | – | 17 | 88.2 | 17 | 5.9 | – | – | 17 | 35.3 |
Hungarya | – | – | 155 | 7.7 | – | – | – | – | – | – | 154 | 7.8 | 154 | 11.7 | 154 | 45.5 |
Ireland | 37 | 2.7 | 37 | 2.7 | 37 | 0 | 8 | 0 | 37 | 16.2 | 37 | 0 | – | – | 37 | 18.9 |
Italy | 1 | NA | 1 | NA | – | – | – | – | 1 | NA | 1 | NA | 1 | NA | 1 | NA |
Latviaa | – | – | 7 | NA | – | – | – | – | – | – | – | – | – | – | – | – |
Lithuaniaa | 56 | 5.4 | 115 | 2.6 | – | – | – | – | – | – | 55 | 1.8 | 139 | 5 | 56 | 75.0 |
Luxembourg | – | – | 21 | 4.8 | – | – | – | – | 21 | 38.1 | 21 | 19.0 | 21 | 19 | 21 | 47.6 |
Maltaa | – | – | 27 | 0 | – | – | – | – | – | – | – | – | – | – | – | – |
Netherlands | 196 | 18.4 | 196 | 19.4 | 196 | 0 | 196 | 0.5 | 196 | 41.3 | 196 | 10.2 | – | – | 196 | 36.7 |
Portugal | 55 | 27.3 | 55 | 25.5 | 55 | 1.8 | – | – | 55 | 78.2 | 55 | 12.7 | – | – | 55 | 67.3 |
Romania | 57 | 1.8 | 57 | 1.8 | – | – | – | – | 57 | 59.6 | 57 | 7.0 | 57 | 5.3 | 57 | 35.1 |
Slovakiaa | – | – | 17 | 5.9 | – | – | – | – | – | – | – | – | 16 | 0 | 30 | 53.3 |
Slovenia | – | – | 43 | 16.3 | – | – | – | – | 44 | 27.3 | 44 | 9.1 | 44 | 6.8 | 44 | 29.5 |
Spain | 58 | 6.9 | 58 | 6.9 | – | – | – | – | 58 | 60.3 | 58 | 6.9 | – | – | 58 | 62.1 |
United Kingdoma | 182 | 7.1 | 627 | 7.3 | – | – | – | – | 85 | 56.5 | 293 | 16.0 | 153 | 21.6 | 109 | 69.7 |
Total (MSs 23) | 1,968 | 9.3 | 2,698 | 8.5 | 723 | 0.3 | 479 | 0.4 | 1,257 | 50.0 | 1,563 | 14.3 | 1,160 | 12.5 | 2,158 | 51.3 |
Icelanda | – | – | 8 | NA | – | – | – | – | – | – | – | – | 8 | NA | – | – |
Norway | – | – | 34 | 11.8 | 13 | 7.7 | – | – | – | – | – | – | 34 | 0 | 13 | 53.8 |
N: number of isolates tested; % Res: percentage of microbiologically resistant isolates [either interpreted as non‐wild type by ECOFFs or clinically non‐susceptible by combining resistant and intermediate categories]; –: no data reported; NA: not applicable – if fewer than 10 isolates were tested, the percentage of resistance was not calculated; MS: Member State.
Provided measured values. Data interpreted by ECDC.
Ciprofloxacin has in several countries been replaced by pefloxacin for screening of fluoroquinolone resistance with disc diffusion, as recommended by EUCAST.
Combined data on the class of sulfonamides and the substance sulfamethoxazole within this group.